The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Fibrin Clot Structure and Function: A Role in the Pathophysiology of Arterial and Venous Thromboembolic Diseases
Open accessAbstract
The formation of fibrin clots that are relatively resistant to lysis represents the final step in blood coagulation. We discuss the genetic and environmental regulators of fibrin structure in relation to thrombotic disease. In addition, we discuss the implications of fibrin structure for treatment of thrombosis. Fibrin clots composed of compact, highly branched networks with thin fibers are resistant to lysis. Altered fibrin structure has consistently been reported in patients with several diseases complicated by thromboembolic events, including patients with acute or prior myocardial infarction, ischemic stroke, and venous thromboembolism. Relatives of patients with myocardial infarction or venous thromboembolism display similar fibrin abnormalities. Low-dose aspirin, statins, lowering of homocysteine, better diabetes control, smoking cessation, and suppression of inflammatory response increase clot permeability and susceptibility to lysis. Growing evidence indicates that abnormal fibrin properties represent a novel risk factor for arterial and venous thrombotic events, particularly of unknown etiology in young and middle-aged patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
Glynn, R. J., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900241 · Cited by 752
Roldan, A. L., Cubellis, M. V., Masucci, M. T., Behrendt, N., Lund, L. R., Danø, K., Appella, E., & Blasi, F. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08132.x · Cited by 603
Why Have Antioxidants Failed in Clinical Trials?
Steinhubl, S. R. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.003 · Cited by 422
Multiscale Mechanics of Fibrin Polymer: Gel Stretching with Protein Unfolding and Loss of Water
Brown, A. E. X., Litvinov, R. I., Discher, D. E., Purohit, P. K., & Weisel, J. W. (2009) · Science · doi:10.1126/science.1172484 · Cited by 416
Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin
Spraggon, G., Everse, S. J., & Doolittle, R. F. (1997) · Nature · doi:10.1038/38947 · Cited by 382
Meltzer, M. E., Lisman, T., de Groot, P. G., Meijers, J. C. M., le Cessie, S., Doggen, C. J. M., & Rosendaal, F. R. (2010) · Blood · doi:10.1182/blood-2010-02-267740 · Cited by 364
Collet, J. P., Allali, Y., Lesty, C., Tanguy, M. L., Silvain, J., Ankri, A., Blanchet, B., Dumaine, R., Gianetti, J., Payot, L., et al. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000241589.52950.4c · Cited by 348
Ariëns, R. A. S., Philippou, H., Nagaswami, C., Weisel, J. W., Lane, D. A., & Grant, P. J. (2000) · Blood · doi:10.1182/blood.v96.3.988 · Cited by 324
Polyphosphate exerts differential effects on blood clotting, depending on polymer size
Smith, S. A., Choi, S. H., Davis-Harrison, R., Huyck, J., Boettcher, J., Rienstra, C. M., & Morrissey, J. H. (2010) · Blood · doi:10.1182/blood-2010-01-266791 · Cited by 307
γ-γ Cross-linking sites in human and bovine fibrin
Chen, R., & Doolittle, R. F. (1971) · Biochemistry · doi:10.1021/bi00800a021 · Cited by 299
Cited by
Fibrinolysis and the control of blood coagulation
Chapin, J. C., & Hajjar, K. A. (2015) · Blood Reviews · doi:10.1016/j.blre.2014.09.003 · Cited by 839
Fibrin Formation, Structure and Properties
Weisel, J. W., & Litvinov, R. I. (2017) · Subcellular Biochemistry · doi:10.1007/978-3-319-49674-0_13 · Cited by 729
Kell, D. B., & Pretorius, E. (2014) · Metallomics · doi:10.1039/c3mt00347g · Cited by 667
Mechanisms of fibrin polymerization and clinical implications
Weisel, J. W., & Litvinov, R. I. (2013) · Blood · doi:10.1182/blood-2012-09-306639 · Cited by 516
New insights into the mechanisms of venous thrombosis
Mackman, N. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60229 · Cited by 436
Cines, D. B., Lebedeva, T., Nagaswami, C., Hayes, V., Massefski, W., Litvinov, R. I., Rauova, L., Lowery, T. J., & Weisel, J. W. (2014) · Blood · doi:10.1182/blood-2013-08-523860 · Cited by 420
Asemi, Z., Zare, Z., Shakeri, H., Sabihi, S.-S., & Esmaillzadeh, A. (2013) · Annals of Nutrition and Metabolism · doi:10.1159/000349922 · Cited by 392
Fibrin Gel as an Injectable Biodegradable Scaffold and Cell Carrier for Tissue Engineering
Li, Y., Meng, H., Liu, Y., & Lee, B. P. (2015) · The Scientific World Journal · doi:10.1155/2015/685690 · Cited by 320
Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?
Boffa, M. B., & Koschinsky, M. L. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r060582 · Cited by 309
“A variety of factors have been shown to alter fibrin clot structure including negatively-charged substances (81).”
BackgroundThrombus Structural Composition in Cardiovascular Disease
Alkarithi, G., Duval, C., Shi, Y., Macrae, F. L., & Ariëns, R. A. S. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315754 · Cited by 293
Self-citationPlasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence
Vaughan, D. E., Rai, R., Khan, S. S., Eren, M., & Ghosh, A. K. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309451 · Cited by 258
Fibrinogen and fibrin: An illustrated review
Pieters, M., & Wolberg, A. S. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12191 · Cited by 272
Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials
D’Ugo, E., Libby, P., & De Caterina, R. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0246 · Cited by 54
Metadata
- Authors
- Undas, A., & Ariëns, R. A. S.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2011-12
- Volume
- 31
- Issue
- 12
- Pages
- e88-99
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2154036638
- Cited by
- 526
- References
- 105
- FWCI
- 22.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.